Please login to the form below
gemcitabine
This page shows the latest gemcitabine news and features for those working in and with pharma, biotech and healthcare.
NICE knocks-back Shire's pancreatic cancer drug Onivyde
The watchdog was reviewing the treatment’s use in England and Wales for metastatic pancreatic cancer that has progressed after gemcitabine-based therapy.
Latest news
-
Ipsen buys cancer business from stripped down Merrimack
For the tens of thousands of patients living with pancreatic cancer in the US who have received prior treatment with gemcitabine, Onivyde represents an important, differentiated innovation, given its proven overall
-
Shire wins EU licence for pancreatic cancer drug Onivyde
following treatment with Lilly's Gemzar (gemcitabine).
-
HIV prevention pill heads July CHMP recommendations
in adults whose disease has progressed after gemcitabine-based therapy.
-
Wales backs NHS use of Abraxane despite NICE rejection
gemcitabine for previously-untreated metastatic pancreatic cancer.
-
Lilly wins European approval for lung cancer drug Portrazza
The European Commission gave the go-ahead to Portrazza (necitumumab) - a new-generation epidermal growth factor receptor (EGFR) blocker - for use in combination with gemcitabine and cisplatin patients with advanced ... In the pivotal SQUIRE trial,
More from news
Approximately 1 fully matching, plus 56 partially matching documents found.
Latest Intelligence
-
The rise of chronic disease in BRIC markets
For late-stage patients, Brazil physicians are more likely to use an anthracycline-based regimen without a taxane in the first line, gemcitabine, paclitaxel or a combination of both in the
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
Marketing strategy in complex environments
cells. A good example of this is the combined use of Abraxane and gemcitabine in the treatment of metastatic adenocarcinoma of the pancreas – Abraxane helps to inhibit cancer cell growth, and ... gemcitabine encourages apoptosis of cell DNA.
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Featured jobs
- FREELANCE Account Manager – Creative Healthcare Advertising – Lo...
-
SUPERB DAY RATES AVAILABLE
-
Senior Programme Executive
-
Salary TBC
- Senior / Principal Regulatory Writer – Home Working - UK or US
-
HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS
- Editor > Senior Editor – Medical Education – London
-
Very competitive with excellent benefits
- Head of Operations/ BUD, Healthcare PR, London – Excellent leade...
-
Excellent Package
- FREELANCE OPPORTUNITIES!!!!! Medical Education - Healthcare Adve...
-
EXCELLENT DAY RATES AVAILABLE
- Senior Account Manager – Med Comms – Kent
-
Salary TBC
- Principal Medical Writer, Medical Communications, Relocate to Ca...
-
Excellent Salary
- Account Manager – Med Comms – London
-
Salary TBC
-
Scientific Director
-
Great salary and bebefits
-
Senior Medical Writer
-
Great salary and benefits
- Senior Medical Writer, Medical Communications, Relocate to Cardi...
-
Excellent Salary
- Senior Account Manager / Account Director
-
Great salary and bebefits
- Editorial Team Leader or Scientific Director
-
£50, 000 - £55, 000 benefits
-
Senior Medical Writer
-
Great salary and bebefits
-
Account Manager, Healthcare PR
-
£40, 000 – £42, 000 great benefits and bonuses
Subscribe to our email news alerts
PMHub
mXm Medical Communications
mXm Medical Communications meets the needs of pharmaceutical marketers and medics who require a highly experienced, bespoke service from their...
Latest intelligence
- Pharma’s isolated islands of innovation
- With service design and technology often failing the patient, why perspective on improving outcomes need to change...
- Uncertainty, austerity and Brexit
- What does it mean for the life science sector?...
- The Holy Grail of HCP Access
- This is the data you need to gain access....
Quick links
Infographics
